Skip to content

Logos Global Management LP

Follow

13F filer, CIK 1792126, San Francisco, CA

Logos Global Management LP reported $1,918,698,941 across 75 holdings for the quarter ended 2026-09-30, in a 13F-HR/A filed 2026-11-19. Its ten largest share positions make up 48.49% of the portfolio.

Accepted , ingested 13F-HR/A 0001172661-26-005476

Period
2026-09-30
Reported value
$1.92B
Holdings
75
Top 10 weight
48.49%
New
31
Sold out
24

Part of the filer group Logos Global Management LP

  • Arsani William
  • Graham Walmsley
  • Logos Global Management GP LLC
  • Logos Global Master Fund LP
  • Logos GP LLC
  • Logos Opportunities Fund IV LP
  • Logos Opportunities Fund V LP
  • Logos Opportunities IV GP LLC
  • Logos Opportunities V GP LLC
How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MDGLnew+100,000$50.4M
PRAXadded+165,000$48.1M
NBIXnew+250,000$35.5M
AXSMnew+175,000$32.3M
ELVNadded+615,000$28.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ERASreduced-6,250,000-$91.6M
CLDXexited-2,100,000-$78.1M
VERAreduced-1,600,000-$51.7M
BNTXreduced-365,000-$35.9M
CMPSexited-2,250,000-$31.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR/A 0001172661-26-005476, largest first. % of portfolio is the value over $1,717,103,941, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 225,000 shares; 2025Q3: 125,000 shares; 2025Q4: 375,000 shares; 2026Q1: 285,000 shares; 2026Q2: 260,000 shares; 2026Q3: 425,000 shares 425,000$124M7.21%+165,000Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,450,000 shares; 2025Q1: 1,600,000 shares; 2025Q2: 1,700,000 shares; 2025Q3: 1,750,000 shares; 2025Q4: 2,000,000 shares; 2026Q1: 2,000,000 shares; 2026Q2: 700,000 shares; 2026Q3: 600,000 shares 600,000$123M7.17%-100,000Timeline
IDYAIDEAYA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,000,000 shares; 2025Q1: 3,500,000 shares; 2025Q2: 3,345,000 shares; 2025Q3: 2,250,000 shares; 2025Q4: 3,125,000 shares; 2026Q1: 3,450,000 shares; 2026Q2: 3,000,000 shares; 2026Q3: 2,850,000 shares 2,850,000$109M6.38%-150,000Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 12,500,000 shares; 2025Q1: 13,000,000 shares; 2025Q2: 15,000,000 shares; 2025Q3: 15,150,000 shares; 2025Q4: 13,000,000 shares; 2026Q1: 11,150,000 shares; 2026Q2: 12,150,000 shares; 2026Q3: 5,900,000 shares 5,900,000$86.5M5.04%-6,250,000Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 415,000 shares; 2025Q4: 400,000 shares; 2026Q1: 675,000 shares; 2026Q2: 1,024,000 shares; 2026Q3: 870,000 shares 870,000$86.1M5.02%-154,000Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 200,000 shares; 2026Q1: 575,000 shares; 2026Q2: 1,000,000 shares; 2026Q3: 975,000 shares 975,000$69.1M4.03%-25,000Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 200,000 shares; 2025Q1: 394,342 shares; 2025Q2: 700,000 shares; 2025Q3: 450,000 shares; 2025Q4: 510,000 shares; 2026Q1: 560,000 shares; 2026Q2: 875,000 shares; 2026Q3: 1,015,000 shares 1,015,000$66.4M3.87%+140,000Timeline
BNTXBIONTECH SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 300,000 shares; 2025Q1: 200,000 shares; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,015,000 shares; 2026Q3: 650,000 shares 650,000$63.9M3.72%-365,000Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 950,000 shares; 2025Q4: 4,200,000 shares; 2026Q1: 3,000,000 shares; 2026Q2: 2,850,000 shares; 2026Q3: 2,150,000 shares 2,150,000$53.6M3.12%-700,000Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 50,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 85,000 shares; 2026Q2: not reported; 2026Q3: 100,000 shares 100,000$50.4M2.93%newTimeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 140,000 shares; 2025Q1: 240,000 shares; 2025Q2: 350,000 shares; 2025Q3: 340,000 shares; 2025Q4: 340,000 shares; 2026Q1: 540,000 shares; 2026Q2: 465,000 shares; 2026Q3: 1,080,000 shares 1,080,000$49.5M2.88%+615,000Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 450,000 shares; 2025Q1: 500,000 shares; 2025Q2: 1,900,000 shares; 2025Q3: 2,400,000 shares; 2025Q4: 1,250,000 shares; 2026Q1: 1,400,000 shares; 2026Q2: 2,550,000 shares; 2026Q3: 3,000,000 shares 3,000,000$48.3M2.81%+450,000Timeline
ACHVACHIEVE LIFE SCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 5,425,000 shares; 2026Q3: 5,951,032 shares 5,951,032$48.1M2.8%+526,032Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,500,000 shares; 2025Q1: 2,300,000 shares; 2025Q2: 2,200,000 shares; 2025Q3: 3,250,000 shares; 2025Q4: 3,500,000 shares; 2026Q1: 3,850,000 shares; 2026Q2: 5,300,000 shares; 2026Q3: 6,000,000 shares 6,000,000$46M2.68%+700,000Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 200,000 shares; 2025Q4: 315,000 shares; 2026Q1: 400,000 shares; 2026Q2: 800,000 shares; 2026Q3: 500,000 shares 500,000$44M2.56%-300,000Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares; 2026Q2: 1,000,000 shares; 2026Q3: 1,350,000 shares 1,350,000$40.9M2.38%+350,000Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 500,000 shares; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 900,000 shares; 2026Q3: 1,250,000 shares 1,250,000$40M2.33%+350,000Timeline
NBIXNEUROCRINE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 200,000 shares; 2025Q1: not reported; 2025Q2: 150,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 250,000 shares 250,000$35.5M2.07%newTimeline
BLTEBELITE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 250,000 shares; 2026Q3: 200,000 shares 200,000$34M1.98%-50,000Timeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 175,000 shares 175,000$32.3M1.88%newTimeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 700,000 shares; 2025Q1: 425,000 shares; 2025Q2: 850,000 shares; 2025Q3: 850,000 shares; 2025Q4: 600,000 shares; 2026Q1: 500,000 shares; 2026Q2: 500,000 shares; 2026Q3: 1,000,000 shares 1,000,000$31.3M1.82%+500,000Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,208,875 shares; 2025Q1: 3,208,875 shares; 2025Q2: 3,208,875 shares; 2025Q3: 3,208,875 shares; 2025Q4: 3,208,875 shares; 2026Q1: 3,208,875 shares; 2026Q2: 3,208,875 shares; 2026Q3: 3,208,875 shares 3,208,875$27.7M1.61%0Timeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 936,914 shares; 2025Q2: 611,914 shares; 2025Q3: 1,227,300 shares; 2025Q4: 950,000 shares; 2026Q1: 1,235,000 shares; 2026Q2: 1,935,000 shares; 2026Q3: 935,000 shares 935,000$25.4M1.48%-1,000,000Timeline
PBLSPARABILIS MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 525,000 shares; 2026Q3: 750,000 shares 750,000$24.2M1.41%+225,000Timeline
APMDAPNIMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,100,000 shares 1,100,000$24.1M1.4%newTimeline
YARWYARROW BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,026,258 shares 1,026,258$23.1M1.35%newTimeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,250,000 shares; 2025Q1: 424,715 shares; 2025Q2: 850,000 shares; 2025Q3: 2,200,000 shares; 2025Q4: 1,550,000 shares; 2026Q1: 2,400,000 shares; 2026Q2: 1,880,000 shares; 2026Q3: 1,445,000 shares 1,445,000$20.7M1.21%-435,000Timeline
MANEVERADERMICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 25,000 shares; 2026Q2: 180,000 shares; 2026Q3: 170,000 shares 170,000$20.6M1.2%-10,000Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 875,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,200,000 shares; 2026Q3: 600,000 shares 600,000$19.4M1.13%-1,600,000Timeline
ODTXODYSSEY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 521,736 shares; 2026Q3: 846,148 shares 846,148$18.8M1.09%+324,412Timeline
SRPTSAREPTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,000,000 shares 1,000,000$18.2M1.06%newTimeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 350,000 shares; 2025Q2: 200,000 shares; 2025Q3: not reported; 2025Q4: 1,750,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 2,675,000 shares; 2026Q3: 1,500,000 shares 1,500,000$17.6M1.02%-1,175,000Timeline
IMCRIMMUNOCORE HLDGS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 575,000 shares; 2025Q3: 850,000 shares; 2025Q4: 850,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 600,000 shares; 2026Q3: 500,000 shares 500,000$15.1M0.88%-100,000Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 700,000 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,100,000 shares 1,100,000$14.7M0.86%newTimeline
OBXOBSIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,066,212 shares 1,066,212$14.6M0.85%newTimeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 300,000 shares; 2026Q3: 250,000 shares 250,000$13.8M0.81%-50,000Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 80,000 shares; 2026Q3: 350,000 shares 350,000$13.3M0.78%+270,000Timeline
ENTXENTERA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 4,411,764 shares 4,411,764$12.8M0.75%newTimeline
DSGNDESIGN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,217,627 shares; 2025Q1: 4,217,627 shares; 2025Q2: 4,217,627 shares; 2025Q3: 3,655,000 shares; 2025Q4: 2,500,000 shares; 2026Q1: 1,950,000 shares; 2026Q2: 3,000,000 shares; 2026Q3: 1,000,000 shares 1,000,000$12.6M0.73%-2,000,000Timeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 553,686 shares; 2025Q3: 600,000 shares; 2025Q4: 600,000 shares; 2026Q1: 482,500 shares; 2026Q2: 1,900,000 shares; 2026Q3: 850,000 shares 850,000$12.4M0.72%-1,050,000Timeline
ETRAELECTRA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,000,000 shares 1,000,000$11.2M0.66%newTimeline
NERVMINERVA NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,311,000 shares; 2026Q1: 3,215,000 shares; 2026Q2: 3,288,777 shares; 2026Q3: 3,288,777 shares 3,288,777$11M0.64%0Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,130,000 shares; 2025Q4: 1,200,000 shares; 2026Q1: 915,000 shares; 2026Q2: 585,000 shares; 2026Q3: 250,000 shares 250,000$9.6M0.56%-335,000Timeline
ATTOATTOVIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 391,426 shares 391,426$6.71M0.39%newTimeline
VKTXVIKING THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 200,000 shares 200,000$6.52M0.38%newTimeline
EDITEDITAS MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,222,000 shares; 2026Q3: 2,222,000 shares 2,222,000$5.71M0.33%0Timeline
TNXPTONIX PHARMACEUTICALS HLDG CQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 550,000 shares 550,000$5.36M0.31%newTimeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,000,000 shares 1,000,000$4.84M0.28%newTimeline
VOGXVOGENX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 205,000 shares 205,000$4.67M0.27%newTimeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 300,000 shares; 2025Q1: 275,000 shares; 2025Q2: 275,000 shares; 2025Q3: 275,000 shares; 2025Q4: 1,375,000 shares; 2026Q1: 1,075,000 shares; 2026Q2: 665,000 shares; 2026Q3: 85,000 shares 85,000$2.87M0.17%-580,000Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 625,000 shares; 2025Q3: 625,000 shares; 2025Q4: 395,000 shares; 2026Q1: 400,000 shares; 2026Q2: 1,125,000 shares; 2026Q3: 200,000 shares 200,000$2.81M0.16%-925,000Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 963,855 shares; 2026Q3: 963,855 shares 963,855$2.63M0.15%0Timeline
TCGXTCGX ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 200,000 shares 200,000$2.5M0.15%newTimeline
UNCYUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 473,562 shares; 2025Q3: 473,563 shares; 2025Q4: 473,563 shares; 2026Q1: 473,563 shares; 2026Q2: 473,563 shares; 2026Q3: 473,563 shares 473,563$2.22M0.13%0Timeline
PTNPALATIN TECHNOLOGIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 140,000 shares; 2026Q1: 140,000 shares; 2026Q2: 130,000 shares; 2026Q3: 129,260 shares 129,260$1.15M0.07%-740Timeline
JATTJATT II ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 100,000 shares; 2026Q3: 100,000 shares 100,000$1.12M0.07%0Timeline
JTTTJATT III ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 100,000 shares 100,000$1.1M0.06%newTimeline
RACCRESEARCH ALLIANCE CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 100,000 shares; 2026Q3: 100,000 shares 100,000$1.08M0.06%0Timeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 134,202 shares; 2025Q1: 134,202 shares; 2025Q2: 109,202 shares; 2025Q3: 83,548 shares; 2025Q4: 23,548 shares; 2026Q1: 23,548 shares; 2026Q2: 23,548 shares; 2026Q3: 23,548 shares 23,548$921K0.05%0Timeline
AMANAMANAT ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 50,000 shares; 2026Q3: 50,000 shares 50,000$534K0.03%0Timeline
LGVNLONGEVERON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 192,308 shares 192,308$517K0.03%newTimeline
GUTSFRACTYL HEALTH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 500,000 shares; 2025Q4: 1,100,000 shares; 2026Q1: 1,000,000 shares; 2026Q2: 1,000,000 shares; 2026Q3: 504,965 shares 504,965$275K0.02%-495,035Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
ERASERASCA INC Stockcall2,500,000$36.6Mnew
AVTXAVALO THERAPEUTICS INC COMMON STOCKcall1,500,000$23Mnew
REPLREPLIMUNE GROUP INC COMMON STOCKcall1,500,000$19.9Mnew
DSGNDESIGN THERAPEUTICS INC COMcall1,500,000$18.9Mnew
SRPTSAREPTA THERAPEUTICS INC COMcall1,000,000$18.2Mnew
SMMTSUMMIT THERAPEUTICS INC COMcall1,000,000$16.9Mnew
BHVNBIOHAVEN LTD COMcall1,000,000$13.3Mnew
RCUSARCUS BIOSCIENCES INC COMcall500,000$12.9Mnew
CMPSCOMPASS PATHWAYS PLC SPONSORED ADScall1,000,000$12.4Mnew
ACHVACHIEVE LIFE SCIENCE INC COMMON STOCKcall1,000,000$8.09Mnew
ALMSALUMIS INC COMcall1,000,000$7.39Mnew
IVAINVENTIVA SA ADScall2,000,000$7.38Mnew
EYPTEYEPOINT INC Stockcall2,000,000$6.54Mnew

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CLDXCELLDEX THERAPEUTICS INC NEW2,100,000$78.1Mshares
CMPSCOMPASS PATHWAYS PLC2,250,000$31.8Mshares
MLYSMINERALYS THERAPEUTICS INC1,050,000$28.3Mshares
REPLREPLIMUNE GROUP INC2,500,000$27.7Mshares
XENEXENON PHARMACEUTICALS INC450,000$27.2Mshares
AVTXAVALO THERAPEUTICS INC1,150,000$21.3Mshares
RCUSARCUS BIOSCIENCES INC650,000$20Mshares
SMMTSUMMIT THERAPEUTICS INC1,350,000$19.7Mshares
FTHFAETH THERAPEUTICS INC722,020$18.1Mshares
DBVTDBV TECHNOLOGIES S A915,000$15Mshares
RYTMRHYTHM PHARMACEUTICALS INC125,000$13.9Mshares
VORVOR BIOPHARMA INC650,000$12Mshares
SRRKSCHOLAR ROCK HLDG CORP200,000$11Mshares
IMMXIMMIX BIOPHARMA INC1,000,000$10.3Mshares
QTTBQ32 BIO INC800,000$10.2Mshares
ANNXANNEXON INC1,500,000$8.56Mshares
RLAYRELAY THERAPEUTICS INC350,000$6.55Mshares
ACADACADIA PHARMACEUTICALS INC250,000$6.33Mshares
AMLXAMYLYX PHARMACEUTICALS INC350,000$6.29Mshares
HELPCYBIN INC750,000$4.96Mshares
TENXTENAX THERAPEUTICS INC300,000$4.37Mshares
QUREUNIQURE NV30,000$1.38Mshares
ACRSACLARIS THERAPEUTICS INC200,000$1.06Mshares
LGVNLONGEVERON INC1,287,000$905Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001172661-26-005128 superseded2026-11-16
13F-HR/A 0001172661-26-005476 baserestatement2026-11-19